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ABSTRACT 
The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management 
of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary 
composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal 
stroke compared to placebo. Liraglutide, a GLP-1 analogue, succeeded to demonstrate reduction on a 
composite outcome including first occurrence of cardiovascular death, nonfatal myocardial infarction 
or non-fatal stroke. These two medications act through different mechanisms and has consequently 
shown different patterns of cardiovascular benefit. In one hand, empagliflozin showed an earlier effect 
compared to those observed using liraglutide. In the other hand, the difference between empagliflozin 
and placebo was driven by a significant reduction in death from cardiovascular causes, with and striking 
disconnect showing no significant between-group difference in the risk of myocardial infarction or 
stroke. In contrast, liraglutide reduced consistently all components of the composite endpoint. Based on 
the different temporal pattern of achieving clinical benefit one might flirt with the idea that liraglutide 
seems to provide a chronic “protection” that better fits in a longer metabolic effect with an impact in 
the progression of atherosclerosis, whilst empagliflozin provides an acute effect compatible with an 
immediate hemodynamic action. After years going from “bench to bedside” in order to discover the 
holy grail of cardioprotection, these 2 new studies suggest that we may have reached this state and it is 
time to go from “bed back to bench side” to understand the mechanisms of this potential paradigm shift.   
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Type 2 diabetes mellitus (T2DM) is expected to affect 552 million people worldwide by 2030. 
T2DM patients have two- to three-fold greater risk of presenting cardiovascular events compared with 
nondiabetics. Furthermore, as many as 80% of T2DM individuals will die from cardiovascular 
complications, such as myocardial infarction, stroke and peripheral vascular disease. 
The link between diabetes and cardiovascular was historically thought to be a solely atherosclerosis 
driven process, although this concept has lately evolved to a more complex interplay between several 
factors affected by T2DM, such as vulnerable blood constituents and vulnerable myocardium, in 
addition to the well-known vulnerable plaque. Hence, T2DM has an impact not only in the rates of 
cardiovascular events, but also in the damage caused by them.  
Unlike the microvascular complications associated with T2DM, evidence that glucose lowering is 
associated with macrovascular benefits is less certain. However, antidiabetic drug effects have also 
been studied beyond their glucose-lowering capacity. In the setting of ischemia-reperfusion injury (IRI), 
known as the additional myocardial damage that negatively impacts on myocardial infarct size due to 
the process of restoring blood flow to the ischemic myocardium[1], antidiabetics have shown 
conflicting results. On one hand, there is modest evidence suggesting that sulfonylureas may further 
impair IRI damage in diabetic patients, whilst  on  the other hand, several preclinical and clinical proof 
of concept studies have suggested that insulin, metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors 
and glucagon-like peptide-1 (GLP-1) analogues confer myocardial protection against IRI[1,2]. 
However we are fortunate that new agents may provide the answer to beneficial cardiovascular 
outcomes; these being the GLP-1 analogues and the sodium–glucose cotransporter 2 (SGLT2) 
inhibitors. 
GLP-1 is an incretin hormone, released from the intestine in response to enteral nutrition, that 
reduces postprandial hyperglycemia by stimulating insulin secretion from β cells in the pancreas and 
inhibiting glucagon secretion from pancreatic α cells, and induces weight loss by acting on brain 
appetite-control centers. The active form, GLP-1(7-36), which is rapidly degraded by the enzyme DPP-
IV, binds GLP-1 receptor, which is expressed not only in pancreatic islet cells, but also in the kidney, 
lung, brain, gastrointestinal tract and heart. Research has manipulated the biology of the entero-insular 
axis producing both injectable GLP-1 agonists that are used as an exogenous source of GLP-1 and oral 
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DPP-4 inhibitors that shield the endogenous peptide from degradation[3]. Findings from our laboratory 
demonstrated for the first time that the administration of either GLP-1 native peptide or the DPP-4 
inhibitor protects against myocardial IRI in the isolated rat heart model through a mechanism not driven 
by the stimulation of insulin secretion, but by the activation of intracellular prosurvival kinases 
cascades[4]. Subsequently, Lonborg et al showed that the infusion of exenatide, a GLP-1analogue, prior 
to primary percutaneous coronary intervention reduces myocardial infarct size patients presenting with 
ST-segment elevation myocardial infarction[5].  
SGLT2 inhibition, reduces rates of hyperglycemia by decreasing glucose reabsorption in the renal 
proximal tubule, thereby increasing urinary glucose excretion[6]. SGLT2 inhibition also decreases 
sodium reabsorption, exerting both a diuretic and natriuretic effect that impact to decrease blood 
pressure and diminish extracellular volume. Overall, SGLT2 inhibitors provides both metabolic and 
hemodynamic benefits. 
The New England Journal of Medicine has published a consecutive series of randomized clinical 
trials (RCTs) with regard to the effect of antidiabetic drugs on cardiovascular outcomes in T2DM 
patients. In 2013, two cardiovascular outcome trials examining DPP-4 inhibitors; the Saxagliptin 
Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in 
Myocardial Infarction 53 (SAVOR-TIMI 53) trial[7] and the Examination of Cardiovascular Outcomes 
with Alogliptin versus Standard of Care (EXAMINE) trial[8], showed that these agents did not have an 
impact on cardiovascular outcomes, but raised safety concerns regarding a potential increased risk of 
hospitalization for heart failure. In 2015, a third trial testing a DPP-4 inhibitor, the trial Evaluating 
Cardiovascular Outcomes with Sitagliptin (TECOS)[9], found that the addition of sitagliptin to usual 
care among patients with glycemic equipoise does not affect rates of major atherosclerotic 
cardiovascular events, including changes in rates of hospitalization for heart failure[9]. In 2015, the 
Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial[10] reported that another 
incretin-based therapy, a GLP-1 receptor analogue, did not significantly affect the rate of major 
cardiovascular events or other serious adverse events in T2DM with a recent acute coronary syndrome.  
After this wave of studies, two recent outcome trials have marked a turning point in cardiovascular 
medicine. The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients 
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(EMPA-REG OUTCOME)[11] trial and the Liraglutide Effect and Action in Diabetes: Evaluation of 
Cardiovascular Outcome Results — A Long Term Evaluation (LEADER) trial[12] have revealed a new 
era in the management of T2DM, demonstrating cardiovascular benefit rather than just lack of harm. 
These two medications act through different mechanisms and has consequently shown different patterns 
of cardiovascular benefit. 
When the SGLT2 inhibitor empagliflozin was administered alongside the standard care among 
patients with T2DM at high risk for cardiovascular, this group showed a lower rate of the primary 
composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal 
stroke compared to placebo[11]. In the same vein, liraglutide, a GLP-1 analogue, succeeded to 
demonstrate reduction on a composite outcome including first occurrence of cardiovascular death, 
nonfatal myocardial infarction or non-fatal stroke[12]. Despite being powered as a noninferiority study, 
the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with 
Type 2 Diabetes (SUSTAIN-6) have also demonstrated that semaglutide (another GLP-1 analogue) 
reduces the risk of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke [13]. We 
intend to focus on the two studies designed to demonstrate superiority, being representative of two 
distinct class of anti-diabetic drugs with cardiovascular effects.  
In this regard although both empagliflozin [11] and liraglutide[12]  have shown cardiovascular 
benefit, they have demonstrated a different temporal and effect pattern. First, the separation between 
treatment and placebo time-to-event curves occurred earlier in the empagliflozin trial, whilst liraglutide 
appears to have a more constant and late effect. Second, the difference between empagliflozin and 
placebo was driven by a significant reduction in death from cardiovascular causes, with and striking 
disconnect showing no significant between-group difference in the risk of myocardial infarction or 
stroke. In contrast, liraglutide reduced consistently all components of the composite endpoint. Although 
these trials were designated to evaluate the effect of these drugs on cardiovascular outcomes, we might 
speculate on the mechanisms behind the observed benefits.  
It is well known that these two drugs have both a metabolic e.g. weight loss effect and a 
haemodynamic effect e.g. blood pressure lowering effect all of which may help with overall myocardial 
benefit. There are no available tools to elucidate how much glucose control contribute to provide 
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cardiovascular benefits as it does with microvascular complications[14]. However, based on the 
different temporal pattern of achieving clinical benefit one might flirt with the idea that liraglutide seems 
to provide a chronic “protection” that better fits in a longer metabolic effect with an impact in the 
progression of atherosclerosis, whilst empagliflozin provides an effect manifested in the short-term 
compatible with an immediate hemodynamic action, such as decrease in blood pressure or increase 
glucagon an inotrope that might be beneficial in heart failure. Imagine what the 2 together could 
achieve? In addition the potential relevance of glucagon should be mentioned. It has been suggested 
that the inhibition of this peptide could diminish metabolic efficiency (as seen with a GLP-1 analogue) 
however the SGLT2 inhibitors have been shown to increase the levels of this peptide which could 
neutralise any such effect. 
Remarkably we might be at the birth of a whole new era in cardioprotection based upon the 
extraordinary results of these two ground-breaking trials. It could be argued that the SGLT2 inhibitor 
fits perfectly the profile of a potential cardioprotective intervention. Its reduction of cardiovascular 
mortality without decrease in neither nonfatal myocardial infarction nor nonfatal stroke suggests that 
the beneficial effect of empagliflozin lies in the survival improvement among T2DM patients 
experiencing a cardiovascular event rather than in the prevention of atherosclerotic events. 
Paradoxically, SGLT2 is not known to be expressed in cardiomyocytes, so after many years 
investigating myocardial signalling pathways cardioprotection might finally arrive through a 
completely different mechanism. In the case of incretin-based therapies, GLP-1 agonists are a promising 
therapy to be used to reduce IRI. GLP-1 agonists are an exogenous source of the molecule with 
improved pharmacokinetic properties that increases pharmacologic levels of GLP-1, whilst DPP-4 
inhibitors “only” shield the endogenous peptide from degradation. Consequently, the level of 
biologically active GLP-1 made available by oral DPP-4 inhibitor therapy is typically three- to five-
fold less than that provided by GLP-1 receptor agonists, potentially making a difference to obtain 
clinical benefit, maybe also through IRI protection. 
After years going from “bench to bedside” in order to discover the holy grail of cardioprotection, 
these 2 new studies suggest that we may have reached this state and it is time to go from “bed back to 
bench side” to understand the mechanisms of this potential paradigm shift.  Therefore if these new anti-
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diabetic agents are telling us that it is possible to protect the myocardium; we need to pay attention and 
exploit this outcome to our advantage. 
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